Comparing Safety Profiles and Health Care Costs

Panelists discuss how safety profiles significantly impact both clinical outcomes and economic sustainability in schizophrenia management. Drugs with fewer adverse effects tend to improve adherence and lower hospital readmissions.

Panelists discuss how second-generation and novel agents generally offer better metabolic and neurologic safety, which can translate into reduced long-term health care spending.

Panelists discuss how evaluating total cost of care rather than upfront medication cost ensures more rational treatment decisions and sustainable systemwide outcomes.